



Express Mail No.: EV 922214824 US
 Deposit: February 14, 2008

Page 1 of 7
 Attorney Docket No.: 24492-020 CIP NATL

Please type a plus sign (+) in this box

PTO/SB (12-97)
 Approved for use through 9/30/00. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number 10/587,529			
				Filing Date July 26, 2006			
				First Named Inventor Cruz			
				Group Art Unit Not Yet Assigned			
				Examiner Name Not Yet Assigned			
				Attorney Docket Number 24492-020 CIP NATL			
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,885,956	03/23/99	Nardi et al.	514	12	
	*A2	5,118,666	06/02/92	Habener, Joel	514	12	
	*A3	5,120,712	06/09/92	Habener	514	12	
	*A4	5,424,286	06/13/95	Eng	514	2	
	*A5	5,512,549	04/30/96	Chen et al.	514	12	
	*A6	5,545,618	08/13/96	Buckley et al.	514	12	
	*A7	5,863,555	01/26/99	Heiber et al.	424	435	
	*A8	5,977,071	11/02/99	Galloway et al.	514	12	
	*A9	5,981,488	11/09/99	Hoffmann	514	12	
	*A10	6,133,235	10/17/00	Galloway et al.	514	12	
	*A11	6,150,327	11/21/00	Sinn et al.	514	8	
	*A12	6,162,907	12/19/00	Habener	536	23.1	
	*A13	6,191,102 B2	02/20/01	DiMarchi et al.	514	2	
	*A14	6,268,343 B1	07/31/01	Knudsen et al.	514	12	
	*A15	6,284,727 B1	09/04/01	Kim et al.	514	12	
	*A16	6,288,301 B1	09/11/01	Nardi et al.	800	18	
	*A17	6,329,336 B1	12/11/01	Bridon et al.	514	2	
	*A18	6,358,924 B1	03/19/02	Hoffman	514	12	
	*A19	6,451,974 B1	09/17/02	Hansen	530	345	
	*A20	6,458,924 B2	10/01/02	Knudsen et al.	530	324	
	*A21	6,506,724 B1	01/14/03	Hiles et al.	514	2	
	*A22	6,514,500 B1	02/04/03	Bridon et al.	424	193.1	
	*A23	6,558,952 B1	05/06/03	Parikh et al.	435	384	
	*A24	6,593,295 B2	07/15/03	Bridon et al.	514	2	
	*A25	6,858,576 B1	02/22/05	Young et al.	514	2	

	*A26	6,872,700 B1	03/29/05	Young et al.	514	2	
	*A27	6,899,883 B2	05/31/05	Dupre	424	198.1	
	*A28	6,902,744 B1	06/07/05	Kolterman et al.	424	489	
	*A29	6,956,026 B2	10/18/05	Beeley et al.	514	12	
	*A30	6,989,148 B2	01/24/06	Dupre	424	198.1	
	*A31	6,992,060 B2	01/31/06	Brand	514	2	
	*A32	7,037,504 B2	05/02/06	Magil et al.	424	198.1	
	*A33	7,202,080 B2	04/10/07	Ramiya et al.	435	325	
	*A34	7,211,557 B2	05/01/07	DiMarchi et al.	514	2	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A35	2001/0006943 A1	07/05/01	Jensen et al.	514	12	
	*A36	2002/0081285 A1	06/27/02	Parikh et al.	424	93.21	
	*A37	2002/0119146 A1	08/29/02	Dupre	424	139.1	
	*A38	2002/0182728 A1	12/05/02	Ramiya et al.	435	366	
	*A39	2003/0032183 A1	02/13/03	Sheridan	435	370	
	*A40	2003/0083259 A1	05/01/03	Efendic et al.	514	12	
	*A41	2003/0119734 A1	06/26/03	Flink et al.	514	12	
	*A42	2003/0224983 A1	12/04/03	Nielson	514	12	
	*A43	2004/0023885 A1	02/05/04	Brand et al.	514	12	
	*A44	2004/0037818 A1	02/26/04	Brand et al.	424	93.21	
	*A45	2004/0209801 A1	10/21/04	Brand et al.	514	12	
	*A46	2004/0209816 A1	10/21/04	Parikh et al.	514	12	
	*A47	2004/0229810 A1	11/18/04	Cruz	514	14	
	*A48	2004/0266682 A1	12/30/04	Cruz	514	12	
	*A49	2006/0183674 A1	08/17/06	Brand et al.	514	11	
	*A50	2006/0189520 A1	08/24/06	Brand et al.	514	12	
	*A51	2006/0234373 A1	10/19/06	Rabinovitch et al.	435	325	
	*A52	2006/0234932 A1	10/19/06	Brand	514	12	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Foreign Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No
	B1	EP	0 507 555 B1	AMERICAN HOME PRODUCTS CORPORATION	10/07/92		
	B2	EP	0 699 686 B1	ELI LILLY & CO.	03/06/96		
	B3	EP	0 708 179 B1	ELI LILLY & CO.	04/24/96		
	B4	EP	0 619 322 B1	SCIOS INC.	10/12/94		
	B5	WO	87/06941	GENERAL HOSPITAL CORPORATION	11/19/87		
	B6	WO	90/11296	GENERAL HOSPITAL CORPORATION	10/04/90		

	B7	WO	91/11457	BUCKLEY ET AL.	08/08/91		
	B8	WO	93/18786	NOVO NORDISK A/S	09/30/93		
	B9	WO	93/19175	THORENS, BERNANRD	09/30/03		
	B10	WO	93/25579	PFIZER, INC.	12/23/93		
	B11	WO	95/19785	RESEARCH TRIANGLE PHARMACEUTICALS LTD.	07/27/95		
	B12	WO	95/31214	LONDON HEALTH ASSOCIATION	11/23/95		
	B13	WO	97/46584	BOEHRINGER MANNHEIM GMBH	12/11/97		
	B14	WO	98/08871	NOVO NORDISK A/S	03/05/98		
	B15	WO	99/38501	TRUSTEES OF TUFTS UNIVERSITY	08/05/99		
	B16	WO	99/43341	NOVO NORDISK A/S	09/02/99		
	B17	WO	99/43705	NOVO NORDISK A/S	09/02/99		
	B18	WO	99/43706	NOVO NORDISK A/S	09/02/99		
	B19	WO	99/43707	NOVO NORDISK A/S	09/02/99		
	B20	WO	99/43708	NOVO NORDISK A/S	09/02/99		
	B21	WO	00/07617	NOVO NORDISK A/S	02/17/00		
	B22	WO	00/42026	NOVO NORDISK A/S; AGOURON PHARMACEUTICALS, INC.	07/20/00		
	B23	WO	00/44400	RPT PHARMA INC.; GENERAL HOSPITAL CORPORATION	08/03/00		
	B24	WO	00/66629	AMYLIN PHARMACEUTICALS, INC.	11/09/00		
	B25	WO	01/04156 A1	ZEALAND PHARMACEUTICALS A/S	01/18/01		
	B26	WO	01/98331 A2	ELI LILLY AND COMPANY	12/27/01		
	B27	WO	02/10195 A2	THERATECHNOLOGIES INC.	02/07/02		
	B28	WO	02/12452 A2	CURIS, INC.	02/14/02		
	B29	WO	02/46227 A2	ELI LILLY AND COMPANY	06/13/02		
	B30	WO	02/055152 A2	WARATAH PHARMACEUTICALS, INC.	07/18/02		
	B31	WO	03/014318 A2	GENZYME CORPORATION	02/20/03		
	B32	WO	03/033671 A2	BRISTOL-MYERS SQUIBB COMPANY, INC.	04/24/03		
	B33	WO	03/040310 A2	WARATAH PHARMACEUTICALS, INC.	05/15/03		
	B34	WO	03/100024 A2	WARATAH PHARMACEUTICALS, INC.; UNIVERSITY OF ALBERTA	12/04/03		
	B35	WO	03/103701 A1	WARATAH PHARMACEUTICALS, INC.	12/18/03		
	B36	WO	2004/005342 A1	ZEALAND PHARMA A/S	01/15/04		
	B37	WO	2004/037195 A2	WARATAH PHARMACEUTICALS, INC.	05/06/04		
	B38	WO	2004/045640 A1	WARATAH PHARMACEUTICALS, INC.	06/03/04		
	B39	WO	2004/096853 A1	WARATAH PHARMACEUTICALS, INC.	11/11/04		
	B40	WO	2004/105780 A2	WARATAH PHARMACEUTICALS, INC.	12/09/04		
	B41	WO	2005/072045 A2	WARATAH PHARMACEUTICALS, INC.	08/11/05		
	B42	WO	2006/002532 A1	WARATAH PHARMACEUTICALS, INC.	01/12/06		
	B43	WO	2007/041833 A1	WARATAH PHARMACEUTICALS, INC.	04/19/07		
	B44	WO	2007/062531 A1	WARATAH PHARMACEUTICALS, INC.	06/07/07		
	B45	WO	2007/095737 A1	WARATAH PHARMACEUTICALS, INC.	08/30/07		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Ahmed et al., "High and Low Affinity Receptors Mediate Growth Effects of Gastrin and GastrinGly on DLD-1 Human Colonic Carcinoma Cells", <i>FEBS Letters</i> , 556:199-203 (2004)
	C2	Andrews et al., "Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas", <i>Journal of Biological Chemistry</i> , 260(7):3910-3914 (1985)
	C3	Baggio et al., "Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, b-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice", <i>J. Biol. Chem.</i> , 275(44):34472-34477 (2000)
	C4	Baggio et al., "Therapeutic approaches to preserve islet mass in type 2 diabetes", <i>Annual Review of Medicine</i> , 57:265-281 (2006)
	C5	Bentley et al., "Human Gastrin: Isolation, Structure and Synthesis", <i>Nature</i> , 209:583-585 (1966)
	C6	Bonato et al., "Guinea Pig 33-Amino Acid Gastrin", <i>Life Science</i> , 39:959-964 (1986)
	C7	Brand et al., "Prolonged Efficacy of Islet Neogenesis Therapy with Gastrin and TGF α in Mature Rats with Preexisting Diabetes", <i>Diabetes</i> , 50(Suppl 2):A338 (Abstract) (2001)
	C8	Breje et al., "The Physiological Role of Prolactin, Growth Hormone and Placental Lactogen in the Regulation of Islet Beta Cell Proliferation", in <i>Pancreatic Growth and Regeneration</i> , Chapter 1, pp. 1-30 (1997)
	C9	Chepurny et al., "Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic β cell lines for use in transplantation", <i>Cell & Tissue Research</i> , 307(2):191-201 (2002)
	C10	Chou et al., "A Radioimmunoassay for LY315902, an Analog of Glucagon-Like Insulinotropic Peptide, and Its Application in the Study of Canine Pharmacokinetics", <i>J. Pharm. Sci.</i> , 86(7):768-773 (1997)
	C11	D'Alessio et al., "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal", <i>J. Clin. Invest.</i> , 93:2263-2266 (1994)
	C12	Deacon et al., "Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig", <i>Diabetes</i> , 47:764-769 (1998)
	C13	Drucker, D.J., "Minireview: The glucagon-like Peptides", <i>Endocrin.</i> , 142(2):521-529 (2001)
	C14	Drucker, D.J., "Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis", <i>Molecular Endocrinology</i> , 17(2):161-171 (2003)
	C15	Dupre et al., "Insulinotropic Effect of Glucagon-Like Peptide I (7-36) Amide in C-Peptide-Positive Type I Diabetes Mellitus", <i>Clinical and Investigative Medicine</i> , 221:B38 (Abstract) (1994)
	C16	Edwards et al., "Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers", <i>Am. J. Physiol. Endocrinol. Metab.</i> , 281:E155-E161 (2001)
	C17	Egan et al., "Glucagon-like Peptide-1 (7-36) Amide (GLP-1) Enhances Insulin-Stimulated Glucose Metabolism in 3T3-L1 Adipocytes: One of Several Potential Extrapancreatic Sites of GLP-1 Action", <i>Endocrinology</i> , 135(5):2070-2075 (1994)
	C18	Elbrond et al., "Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects", <i>Diabetes Care</i> , 25(8):1398-1404 (2002)
	C19	Fehmann et al., "Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells", <i>Endocrinology</i> , 130(1):159-166 (1992)
	C20	Garia-Ocana et al., "Peptide Growth Factors", <i>J. Clin. Endocrinol. Metab.</i> , 86(3):984-988 (2001)
	C21	GenBank Accession No. AAH69762, July 2006

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C22	GenBank Accession No. NP_000796, November 2007
	C23	Ghiglione et al., "How Glucagon-Like is Glucagon-Like peptide?", <i>Diabetologia</i> , 27:599-600 (1984)
	C24	Goke et al., "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-Amide an Antagonist at the Glucagon-Like Peptide 1-(7-36)-Amide Receptor of Insulin-Secreting Beta-Cells", <i>J. Biol. Chem.</i> , 268(26):19650-19655 (1993)
	C25	Gromada et al., "Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1", <i>Eur. J. Physiol.</i> , 435:583-594 (1998)
	C26	Gromada et al., "Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting beta.TC3 Cells: Role of PKA-independent Mechanisms", <i>Brit. Jour. Phar.</i> , 118:769-775 (1996)
	C27	Gromada et al., "Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic beta-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling", <i>Diabetes</i> , 47(1):57-65 (1998)
	C28	Gutniak et al., "Glucagon-Like Insulinotropic Peptide 1 (7-36)--New Approach to Treating Diabetes?," <i>Diabetologia</i> , 33(Supp.):A73 (1990)
	C29	Gutniak et al., "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus", <i>New Eng. J. of Medicine</i> , 326(20):1316-1322 (1992)
	C30	Hargrove et al., "Glucose-Dependent Action of Glucagon-Like Peptide-1(7-37) In Vivo During Short- or Long-Term Administration", <i>Metabolism</i> , 44(9):1231-1237 (1995)
	C31	Hargrove et al., "Comparison of the Glucose Dependency of Glucagon-Like Peptide-1(7-37) and Glyburide In Vitro and In Vivo", <i>Metabolism</i> , 45(3):404-409 (1996)
	C32	Hendrick et al., "Glucagon-like Peptide-1-(7-37) Suppress Hyperglycemia in Rats", <i>Metabolism</i> , 42(1):1-6 (1993)
	C33	Hendrick et al., "Glucagon-like Peptide 1 (7-37) Blunts Postprandial Glycaemic Excursion in Rats with Mild Diabetes", <i>Diabetologia</i> , 32(7):496A (Abstract) (1989)
	C34	Holst, "Glucagon Peptide 1: A Newly Discovered Gastrointestinal Hormone", <i>Gastroenterology</i> , 107(6):1848-1855 (1994)
	C35	Holst, J.J., "Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1", <i>Diabetes Metab. Res. Rev.</i> , 18:430-441 (2002)
	C36	Hui et al., "Glucagon-like peptide 1 induces differentiation of islet duodenalhomeobox-1-positive pancreatic ductal cells into insulin-secreting cells", <i>Diabetes</i> , 50:785-796 (2001)
	C37	Hvidberg et al., "Effect of Glucagon-like Peptide-1 (proglucagon78-107amide) on Hepatic Glucose Production in Healthy Man", <i>Metabolism</i> , 43(1):104-108 (1994)
	C38	Iritani et al., "Oral Triacylglycerols Regulate Plasma Glucagon-Like Peptide-1(7-36) and Insulin Levels in Normal and Especially in Obese Rats", <i>J. Nutr.</i> , 129:46-50 (1999)
	C39	Knudsen et al., "Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration", <i>J. Med. Chem.</i> , 43(9):1664-1669 (2000)
	C40	Kopin et al., "The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands", <i>J. Biol. Chem.</i> , 270(10):5019-5023 (1995)
	C41	Korc, M.J., "Islet Growth Factors: Curing Diabetes and Preventing Chronic Pancreatitis?", <i>Clin. Invest.</i> , 92:1113-1114 (1993)
	C42	Kreymann et al., "Glucagon-like peptide-1 7-36: A physiological incretin in man", <i>The Lancet</i> , 2:1300-1304 (1987)
	C43	Kreymann et al., "Glucagon-like Peptide-1 7-36 Amide, A New Brain-Gut Hormone and Its Effect of Pancreatic Endocrine Function in Man", <i>Biomed. Res.</i> , 9(Supp. 3):207-211 (1988)

C44	Larsen et al., "Glucagons-Like Peptide-1 Infusion Must Be Maintained For 24 H/Day To Obtain Acceptable Glycemia In Type 2 Diabetic Patients Who Are Poorly Controlled On Sulphonylurea Treatment", <i>Diabetes Care</i> , 24(8):1416-1421 (2001)
C45	Larsen et al., "Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats", <i>Diabetes</i> , 50:2530-2539 (2001)
C46	Lin et al., "Introduction of sulfhydryl groups into proteins at carboxyl sites", <i>Biochim. Biophys. Acta</i> , 1038:382-385 (1990)
C47	Merrifield, R.B., "Solid Phase Peptide Synthesis: I. The Synthesis of Tetrapeptide", <i>J. Am. Chem. Assoc.</i> , 85:2149-2154 (1963)
C48	Moller, D.E., "New Drug Targets for Type 2 Diabetes and the Metabolic Syndrome", <i>Nature</i> , 414:821-827 (2001)
C49	Morales et al., "Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats", <i>Diabetes</i> , 46:1264-1269 (1997)
C50	Movassat et al., "Exendin-4 upregulates expression of PDX-1 and hastens differentiation and maturation of human fetal pancreatic β cells", <i>Diabetes</i> , pp. A341 (Abstract) (2001)
C51	Nathan et al., "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", <i>Diabetes Care</i> , 15(2):270-276 (1992)
C52	Nauck et al., "Preserved Incretin Activity of Glucagon-like Peptide 1 [7-36 Amide] but Not of Synthetic Human Gastric Inhibitory Polypeptide in Patients with Type 2 Diabetes Mellitus", <i>J. Clin. Invest.</i> , 91:301-307 (1993)
C53	Nauck, M.A., "Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective", <i>Acta Diabetol.</i> , 35:117-129 (1998)
C54	Nauck et al., "Additive Insulinotropic Effects of Exogenous Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1-(7-36) Amide Infused at Near-Physiological Insulinotropic Hormone and glucose Concentrations", <i>J. of Clin. Endo. and Meta.</i> , 76(4):912-917 (1993)
C55	Orskov et al., "Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide-1 in Humans", <i>Diabetes</i> , 43:535-539 (1994)
C56	Parkes et al., "Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 in Vivo and in Vitro", <i>Metabolism</i> , 50(5):583-589 (2001)
C57	Patel et al., "Treatment of non-insulin-dependent diabetes mellitus", <i>Expert Opinion Investig. Drugs</i> , 12(4):623-633 (2003)
C58	Perfetti et al., "Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic- Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats", <i>Endocrinology</i> , 141(12):4600-4605 (2000)
C59	Rehfeld, J.F., "The New Biology of Gastrointestinal Hormones", <i>Physiol. Rev.</i> , 78(4):1087-1108 (1998)
C60	Reimer et al., "Dose-Dependent Inhibition by Ghrelin of Insulin Secretion in the Mouse", <i>Endocrinology</i> , 144(3):916-921 (2003)
C61	Ritzel et al., "Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance", <i>Diabetes</i> , 50:776-784 (2001)
C62	Schmidt et al., "Glucagon-Like peptide-1 but not Glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets", <i>Diabetologia</i> , 28:704-707 (1985)
C63	Singh et al., "Novel Gastrin Receptors Mediate Mitogenic Effects of Gastrin and Processing Intermediates of Gastrin on Swiss 3T3 Fibroblasts", <i>J. Biol. Chem.</i> , 270(15):8429-8438 (1995)
C64	Stoffers et al., "Early-Onset Type-II Diabetes Mellitus (MODY4) Linked to IPF1", <i>Nat. Genet.</i> , 17:138-139 (1997)
C65	Sturis et al., "Long-Acting GLP-1 Derivative NN2211 Markedly Attenuates Diabetes Development in the Male Zucker Diabetic Fatty Rat", <i>Diabetologia</i> , A145 (Abstract) (2000)

C66	Todd et al., "Subcutaneous Glucagon-Like Peptide-1 Improves Postprandial Glycaemic Control Over a 3-Week Period in Patients With Early Type 2 Diabetes", <i>Clin. Science</i> , 95:325-329 (1998)
C67	Tourrel et al., "Glucagon-Like Peptide-1 and Exendin-4 Stimulate Beta-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age", <i>Diabetes</i> , 50:1562-1570 (2001)
C68	Tourrel et al., "Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the Beta-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-1 or Exendin-4", <i>Diabetes</i> , 51:1443-1452 (2002)
C69	"Transition Therapeutics Confirms Effectiveness of Islet Neogenesis Therapy in Reducing Diabetic Symptom", Transition Therapeutics Press Release, April 17, 2002
C70	"Transition Therapeutics Inc. Receives Approval to Initiate Phase I Clinical Trial for Islet Neogenesis Therap", Transition Therapeutics Press Release, September 20, 2002
C71	"Transition Therapeutics' I.N.T.™ Treatment Stimulates Regeneration of Human Insulin-Producing Cell", Transition Therapeutics Press Release, September 26, 2002
C72	"Transition Therapeutics' I.N.T.™ Treatment Increases Survival", Transition Therapeutics Press Release, September 27, 2002
C73	Uttenthal et al., "Molecular forms of Glucagon-like peptide-1 in human pancreas and Glucagonomas", <i>The Journal of Clinical Endocrinology and Metabolism</i> , 61:472-479 (1985)
C74	Villanueva-Penacarrillo et al., "Increased Glucagon-like Peptide 1 (7-36) Amide Binding in Adipose Tissue from Non-Insulin Dependent and Insulin-Dependent Diabetic Patients", <i>Diabetes Nutr. Metab. Clin. Exp.</i> , 7(3):143-148 (1994)
C75	von Herrath, M., "EI-INT Transition Therapeutics/Novo Nordisk", <i>Current Opinion Investig. Drugs</i> , 6(10):1037-1042 (2005)
C76	Wang et al., "Glucagon-Like Peptide-1 Can Reverse the Age-Related Decline in Glucose Tolerance in Rats", <i>J. Clin. Invest.</i> , 99(12):2883-2889 (1997)
C77	Wang et al., "Glucagon-Like Peptide-1 Is a Physiological Incretin in Rat", <i>J. Clin. Invest.</i> , 95:417-421 (1995)
C78	Wettergren et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man", <i>Digestive Diseases and Sciences</i> , 38(4):665-673 (1993)
C79	Xu et al., "Exendin-4 stimulates both beta-cell proliferation and neogenesis", <i>Diabetes</i> , 48:2270-2276 (1999)
C80	Young et al., "Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4: Studies in Obese Diabetic (ob/ob, db/db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca mulatta)", <i>Diabetes</i> , 48:1026-1034 (1999)
C81	Zhou et al., "Glucagon-Like Peptide 1 and Exendin-4 Convert Pancreatic AR42J Cells into Glucagon- and Insulin-Producing Cells", <i>Diabetes</i> , 48:2358-2366 (1999)

* By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A1-A34 and U.S. Published Applications A35-A52 are not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.